|

ADX-097 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Akebia Therapeutics1

Indications

  • C3 (Complement Component 3) Glomerulopathy1
  • Lupus Nephritis (LN)1
  • IgA Nephropathy1
  • Lupus1

Lawrenceville, Georgia1 trial

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Investigator Site #1

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.